Show simple item record

dc.contributor.advisor Chilkoti, Ashutosh en_US
dc.contributor.author Schaal, Jeffrey Laurence en_US
dc.date.accessioned 2012-05-25T20:18:16Z
dc.date.available 2012-05-25T20:18:16Z
dc.date.issued 2012 en_US
dc.identifier.uri http://hdl.handle.net/10161/5534
dc.description Thesis en_US
dc.description.abstract <p>Brachytherapy has emerged as one of the pre-eminent radiotherapy modalities for the treatment of prostate cancer. Current clinical methods utilize titanium encased radioactive seeds that are fixated within the prostate and permanently implanted. A novel brachytherapy alternative that has been developed to improve the delivery of radionuclide intratumorally is the synthetically designed elastin-like polypeptide (ELP). ELP can be injected in fluid form and undergoes an inverse phase transition to a biocompatible coascervate capable of serving as a biocompatible, intratumoral depot. Utilizing a previously developed ELP with a 7 tyrosine C-terminus tail, the therapeutic efficacy of ELP as a radioactive depot for treating prostate cancer was examined in a preclinical, orthotopic model. The orthotopic prostate model was first established by xenografting Bioware® PC-3M-luc-C6 cells into immunoincompetent, Balb/c nude mice. A non-invasive method for tracking tumor progression in vivo was developed using a correlation model comparing quantitative luminescent flux emitted from the cell line against the actual tumor size. The correlation between flux and tumor volume was determined to as Volume = 7.234x10-9x - 18.54, (±21.7%), where x is the supine photon flux measured from a 10 second exposure taken 18 minutes after D-luciferin injection. Radionuclide conjugation of 131I to ELP was conducted using the established IODO-GEN reaction methodology and mice were administered a therapeutic dose of 2mCi / 40µl ELP / 150 mm3 prostate tumor. Intratumoral deposition resulted in tumor regression in 90.9% of treated mice (n=11); 63.6% of which achieved tumor size reduction by over 60%. Radioactivity measurements demonstrate an 89.9% ELP depot retention over 2 weeks. Survival rates of the test group (64%) compared with controls (100%, n=14) indicate further testing is required to optimize radionuclide dosimetry.</p> en_US
dc.subject Biomedical engineering en_US
dc.subject Brachytherapy en_US
dc.subject Elastin-like polypeptide en_US
dc.subject Intratumoral Depot en_US
dc.subject Phase transition en_US
dc.subject Prostate Cancer en_US
dc.subject Thermal sensitivity en_US
dc.title Efficacy of ELP as an Intratumoral Depot for Radionuclide Therapy of PC-3 Prostate Cancer in an Orthotopic, Nude Mouse Model en_US
dc.type Thesis en_US
dc.department Biomedical Engineering en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record